Greece says on track to meet EU-IMF targets
Greece said on Tuesday its budget was in surplus, not counting interest payments, and that it was on course to hit fiscal targets and fulfill conditions to seek additional debt relief from its international lenders. The central government had a primary budget surplus of 2.92 billion euros ($3.87 billion) between January and August, the finance ministry said. It compares with an interim target for a deficit of 2.5 billion euros in the period, it said. Reaching a primary surplus this year is the main goal of the debt-laden country’s government. Hitting that target would trigger a clause in its international bailout allowing Athens to seek additional debt relief from its lenders.
IAEA cuts nuclear energy growth projection
The United Nations’ atomic agency has cut its long-term outlook for nuclear energy growth for a third year in a row, in part because of hesitancy following Japan’s Fukushima disaster. The industry could, however, still nearly double its capacity by 2030 due to expansion in Asia. Overall nuclear generating capacity will grow by between 17 and 94% by 2030 depending on a wide range of factors such as global economic growth, the International Atomic Energy Agency said. That was down from 25 and 100%, respectively, from last year’s forecast.
Norway’s center-right to start government talks
Conservative Party leader Erna Solberg, poised to become Norway’s new Prime Minister after a landslide victory in the country’s parliamentary elections, says she aims to form a broad coalition government, including all four center-right parties. Solberg said Tuesday she will draw up a plan for government negotiations this week with the anti-immigration Progress Party, the Liberal Party and the Christian Democrats. Solberg’s Conservative Party emerged as the winners in Norway’s parliamentary elections Monday, securing 48 of the total 169 seats in parliament. The Progress Party got 29 seats, the Liberal Party nine and the Christian Democrats 10.
Europe approves first biosimilar antibody drug
The European Commission has approved the first copycat version of an antibody-based drug, clearing the way for increased competition for the makers of multi-billion dollar biotechnology drugs to treat complex diseases. Tuesday’s final